John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.